New hope for lymphoma patients: experimental drug combo enters final trial phase

NCT ID NCT07355283

Not yet recruiting Disease control Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding the experimental drug IMM0306 to standard lenalidomide can improve outcomes for people with follicular lymphoma that has returned or stopped responding to treatment. About 198 participants will be randomly assigned to receive either IMM0306 or a placebo, both with lenalidomide. The study measures how many achieve complete remission and how long they live without the disease worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMM0306 (Amulirafusp alfa) combined with lenalidomide
What this could lead to: If successful, this combination could offer a new treatment option that helps more people with follicular lymphoma achieve complete remission and delay disease progression.
What could go wrong: This is still an experimental treatment. Even in Phase 3, it may not prove better than existing options, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.